These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24269287)

  • 1. Preparation and characterization of sustained-release rotigotine film-forming gel.
    Li X; Zhang R; Liang R; Liu W; Wang C; Su Z; Sun F; Li Y
    Int J Pharm; 2014 Jan; 460(1-2):273-9. PubMed ID: 24269287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies.
    Wang Z; Mu HJ; Zhang XM; Ma PK; Lian SN; Zhang FP; Chu SY; Zhang WW; Wang AP; Wang WY; Sun KX
    Int J Nanomedicine; 2015; 10():633-44. PubMed ID: 25609965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation.
    Cawello W; Braun M; Andreas JO
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):475-481. PubMed ID: 29332198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies.
    Elshoff JP; Braun M; Andreas JO; Middle M; Cawello W
    Clin Ther; 2012 Apr; 34(4):966-78. PubMed ID: 22401642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial.
    Cawello W; Wolff HM; Meuling WJ; Horstmann R; Braun M
    Clin Pharmacokinet; 2007; 46(10):851-7. PubMed ID: 17854234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rotigotine: the first new chemical entity for transdermal drug delivery.
    McAfee DA; Hadgraft J; Lane ME
    Eur J Pharm Biopharm; 2014 Nov; 88(3):586-93. PubMed ID: 25173087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery.
    Cawello W; Braun M; Boekens H
    Drug Metab Dispos; 2009 Oct; 37(10):2055-60. PubMed ID: 19608695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel UHPLC-MS/MS method for the determination of rotigotine in the plasma of patients with Parkinson's disease.
    Mohamed S; Riva R; Contin M
    Biomed Chromatogr; 2017 Sep; 31(9):. PubMed ID: 28168729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing different salt forms of rotigotine to improve transdermal iontophoretic delivery.
    Ackaert OW; Eikelenboom J; Wolff HM; Bouwstra JA
    Eur J Pharm Biopharm; 2010 Feb; 74(2):304-10. PubMed ID: 19969079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The direct analysis of drug distribution of rotigotine-loaded microspheres from tissue sections by LESA coupled with tandem mass spectrometry.
    Xu LX; Wang TT; Geng YY; Wang WY; Li Y; Duan XK; Xu B; Liu CC; Liu WH
    Anal Bioanal Chem; 2017 Sep; 409(22):5217-5223. PubMed ID: 28702764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder.
    Sun F; Sui C; Zhou Y; Liu X; Shi Y; Wu Y; Li Y
    Int J Pharm; 2013 Sep; 454(1):532-8. PubMed ID: 23891744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro.
    Nugroho AK; Li G; Grossklaus A; Danhof M; Bouwstra JA
    J Control Release; 2004 Apr; 96(1):159-67. PubMed ID: 15063038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of palmitic acid on the characteristics and release profiles of rotigotine-loaded microspheres.
    Wang A; Liang R; Liu W; Sha C; Li Y; Sun K
    Pharm Dev Technol; 2016; 21(1):3-7. PubMed ID: 25697744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: In vitro characterization and in vivo behavior study.
    Wang F; Yang Z; Liu M; Tao Y; Li Z; Wu Z; Gui S
    Int J Pharm; 2020 Mar; 577():119046. PubMed ID: 31982559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PREPARATION, IN VITRO AND IN VIVO CHARACTERIZATION OF HYDROPHOBIC PATCHES OF A HIGHLY WATER SOLUBLE DRUG FOR PROLONGED PLASMA HALF LIFE: EFFECT OF PERMEATION ENHANCERS.
    Yaqoob A; Ahmad M; Mahmood A; Sarfraz RM
    Acta Pol Pharm; 2016 Nov; 73(6):1639-1648. PubMed ID: 29634120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
    Garnock-Jones KP
    Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotigotine Schwarz Pharma.
    Mucke HA
    IDrugs; 2003 Sep; 6(9):894-9. PubMed ID: 12964070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
    Boroojerdi B; Wolff HM; Braun M; Scheller DK
    Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation on the effect of deep eutectic formation on drug-polymer miscibility and skin permeability of rotigotine drug-in-adhesive patch.
    Liu C; Qu X; Song L; Shang R; Wan X; Fang L
    Int J Pharm; 2020 Jan; 574():118852. PubMed ID: 31759103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.